VENTYX BIOSCIENCES INC (VTYX)

US92332V1070 - Common Stock

5.805  -0.06 (-0.94%)

After market: 5.77 -0.04 (-0.6%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (3/27/2024, 8:00:03 PM)

After market: 5.77 -0.04 (-0.6%)

5.805

-0.06 (-0.94%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap408.85M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VTYX Daily chart

Company Profile

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 99 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX958 (TYK2 Inhibitor), VTX002 (S1P1R Modulator), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor.

Company Info

VENTYX BIOSCIENCES INC

12790 El Camino Real, Suite 200

San Diego CALIFORNIA

P: 18589452393

Employees: 99

Website: https://ventyxbio.com/

VTYX News

News Image10 hours ago - Bragar Eagel & SquireBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm
News Image11 hours ago - TheNewswire.comROSEN, A RESPECTED AND LEADING FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

WHY: NEW YORK, NY - (NewMediaWire) - March 27, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.

News Image11 hours ago - NewMediaWireROSEN, A RESPECTED AND LEADING FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image16 hours ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - VTYX

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX)...

News Imagea day ago - Levi & Korsinsky, LLPInvestors in Ventyx Biosciences, Inc. Should Contact Levi & Korsinsky Before April 30, 2024 to Discuss Your Rights - VTYX

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) of a class action securities...

News Imagea day ago - TheNewswire.comROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - VTYX

WHY: NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s October 21, 2021 initial public offering (the “IPO” or “Offering”); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the “Class Period”), of the important April 30, 2024 lead plaintiff deadline.

VTYX Twits

Here you can normally see the latest stock twits on VTYX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example